Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM NASDAQ:ARAV NASDAQ:CMRX NASDAQ:MRKR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.84-1.2%$0.88$0.65▼$4.47$5.33M0.352,517 shs16,107 shsARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ACMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.94 million shsN/AMRKRMarker Therapeutics$1.44-1.4%$1.45$0.81▼$4.07$24.01M1.43247,875 shs60,322 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group-2.14%-3.91%-3.93%+14.86%-0.55%ARAVAravive0.00%0.00%0.00%0.00%0.00%CMRXChimerix0.00%0.00%0.00%0.00%0.00%MRKRMarker Therapeutics-3.31%+0.69%+3.55%-12.05%+28.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.84-1.2%$0.88$0.65▼$4.47$5.33M0.352,517 shs16,107 shsARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ACMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.94 million shsN/AMRKRMarker Therapeutics$1.44-1.4%$1.45$0.81▼$4.07$24.01M1.43247,875 shs60,322 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group-2.14%-3.91%-3.93%+14.86%-0.55%ARAVAravive0.00%0.00%0.00%0.00%0.00%CMRXChimerix0.00%0.00%0.00%0.00%0.00%MRKRMarker Therapeutics-3.31%+0.69%+3.55%-12.05%+28.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 1.00SellN/AN/AARAVAravive 0.00N/AN/AN/ACMRXChimerix 0.00N/AN/AN/AMRKRMarker Therapeutics 2.25Hold$10.00592.04% UpsideCurrent Analyst Ratings BreakdownLatest CMRX, MRKR, APM, and ARAV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026MRKRMarker Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K12.66N/AN/A$2.17 per share0.39ARAVAraviveN/AN/AN/AN/AN/AN/ACMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94MRKRMarker Therapeutics$3.55M6.79N/AN/A$1.01 per share1.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$1.36MN/AN/AN/AN/AN/AN/AN/AN/AARAVAraviveN/A-$0.90N/AN/AN/AN/AN/AN/AN/ACMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%N/AMRKRMarker Therapeutics-$12.16M-$0.85N/AN/AN/A-343.03%-80.86%-67.04%5/21/2026 (Estimated)Latest CMRX, MRKR, APM, and ARAV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026MRKRMarker Therapeutics-$0.18N/AN/AN/A$0.68 millionN/A3/18/2026Q4 2025MRKRMarker Therapeutics-$0.21-$0.04+$0.17-$0.04$0.68 million$1.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/AARAVAraviveN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.780.78ARAVAraviveN/AN/AN/ACMRXChimerixN/A6.336.33MRKRMarker TherapeuticsN/A8.398.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%ARAVAravive35.80%CMRXChimerix45.42%MRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%ARAVAravive60.40%CMRXChimerix13.10%MRKRMarker Therapeutics5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group306.35 million2.29 millionNot OptionableARAVAravive20N/AN/ANo DataCMRXChimerix9093.80 million78.15 millionNo DataMRKRMarker Therapeutics6016.67 million15.72 millionNot OptionableCMRX, MRKR, APM, and ARAV HeadlinesRecent News About These CompaniesMarker Therapeutics (MRKR) price target decreased by 12.83% to 8.02April 9, 2026 | msn.comMARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue EstimatesMarch 18, 2026 | zacks.comMarker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-OncologyMarch 18, 2026 | quiverquant.comQMarker Therapeutics Reports Year-End 2025 Corporate and Financial ResultsMarch 18, 2026 | globenewswire.comMarker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 18, 2026 | globenewswire.comGood Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell TechnologyJanuary 26, 2026 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)January 22, 2026 | theglobeandmail.comMRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to KnowJanuary 21, 2026 | zacks.comMarker Therapeutics, Inc. Common Stock (MRKR)January 9, 2026 | nasdaq.comMARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?January 7, 2026 | zacks.com5 Small Drug Stocks to Buy as Industry Recovery Picks UpJanuary 7, 2026 | zacks.comMarker Therapeutics announces publication on MAR-T cells in pancreatic cancerJanuary 5, 2026 | msn.comBaylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic CancerJanuary 5, 2026 | globenewswire.comHere's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash WiselyDecember 18, 2025 | finance.yahoo.comHC Wainwright & Co. initiates coverage of Marker Therapeutics (MRKR) with buy recommendationDecember 8, 2025 | msn.comMarker Therapeutics initiated with a buy at HC WainwrightDecember 8, 2025 | msn.comMarker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdatesNovember 14, 2025 | globenewswire.comMarker Therapeutics appoints Penkus Corzo to board of directorsNovember 5, 2025 | msn.comMarker Therapeutics appoints Kathryn Penkus Corzo to Board of DirectorsNovember 5, 2025 | globenewswire.comCanaccord Genuity Keeps Their Buy Rating on Marker Therapeutics (MRKR)November 4, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026Detroit's Great Divide: Two Titans, Two Paths to Profit By Jeffrey Neal Johnson | April 9, 2026CMRX, MRKR, APM, and ARAV Company DescriptionsAptorum Group NASDAQ:APM$0.86 +0.01 (+0.78%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Aravive NASDAQ:ARAV$0.04 0.00 (0.00%) As of 05/5/2026Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Chimerix NASDAQ:CMRXChimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Marker Therapeutics NASDAQ:MRKR$1.44 -0.02 (-1.37%) Closing price 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
